Name
GS3-05: Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial - Commentary by: Hope S. Rugo, MD
Date & Time
Thursday, December 4, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL